This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Clostridium Difficile Vaccines (West)

NEW YORK , Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue: MarketVIEW: Clostridium difficile vaccines (West)

Clostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever, tachycardia and psuedomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy. Although CDAD can be managed usually by stopping antibiotic therapy or the use of metronidazole and vancomycin treatment, patient mortality can still reach 6-30%. In some patients with toxic megacolon who require surgical intervention or colectomy, mortality can reach even higher rates of 35-50%. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of C.diff vaccines to 2030 in the major Western markets. All three potential vaccine indications are modelled: Community prophylaxis (PX), Hospital prophylaxis (PX) and preventation of CDI recurrences (TX) with a focus on key target populations and latest predicted profile profiles. Also included is an in-depth epidemiology forecast to 2030 including number of CDI cases per country drawing upon latest surveillance data (pan-European survey). A discussion of the potential impact of latest pipeline developments/launches e.g. Fidoxamicin (OPT-80) and MK-3415A (monoclonals) on the vaccine proposition is covered. THIS PRODUCT IS AN EXECUTIVE PRESENTATION + 3 MODELS Contents – Executive presentation (MS PowerPoint based)Author's noteExecutive summaryKey commercial outputs: Community PX productKey commercial outputs: Hospital PX productKey commercial outputs: prevention of relapses (TX)Overview of latest changes – February 2012Epidemiology forecast – latest dataEpidemiology: number of CDI cases (2008-2030)Epidemiology: incidence per country 2000-2030Epidemiology: possible scenarios to 2030C.diff vaccines: Epidemiology: possible scenarios to 2030C.Diff vaccines: three potential markets modelledC.Diff vaccines: example target populationsCommunity prophylaxis: major model assumptionsPrevention of CDI recurrences: major model assumptionsHospital prophylaxis: major model assumptionsCommunity prophylaxis: available market ($000s) to 2030Community prophylaxis: competitor revenues ($000s) to 2030Prevention of CDI recurrences: available market ($000s) to 2030Prevention of CDI recurrences: competitor revenues ($000s) to 2030Hospital prophylaxis: available market ($000s) to 2030Hospital prophylaxis: competitor revenues ($000s) to 2030Markets covered to 2030Pricing assumptions appliedCompetitor landscape: overviewSanofi Pasteur: ACAM-CDIFFACAM-CDIFF clinical development planIntercell AG: IC84AntibioticsMonoclonal antibodiesEpidemiology: situation overviewAcute care hospitals: USLTCFs: USAcute care hospitals: pan-EuropeanAcute care hospitals: UK ( Scotland, Wales and N.I.)Acute care hospitals: GermanyAcute care hospitals: FranceAcute care hospitals: SpainAcute care hospitals: ItalyAcute care hospitals: CanadaAcute care hospitals: AustraliaEpidemiology: forecast trendsDefinitions of CDI exposuresFollow-on vaccines: market share analysisBibliographyDisclaimerAbout VacZine AnalyticsPAGES: ~95 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)Note: Three models are included with this productHospital vaccination (PX)Community vaccination (PX)Prevention of CDI replases (TX)United StatesCanadaUKFranceGermanyItalySpainOther EU

To order this report:: MarketVIEW: Clostridium difficile vaccines (West)

Nicolas BombourgReportlinkerEmail: nicolasbombourg@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs